The deal between the White House and Democrats would raise the debt ceiling for two years and permanently end the sequester.Politicsread more
The construction industry is heavily dependent on Hispanic and Latino workers, a workforce that diminished during the last housing crisis and has not come close to full...Real Estateread more
"Even a 50-basis point reduction would still keep the Fed funds rate well above zero," Shelton told The Washington Post in an email.The Fedread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
"Whether it's this year or next year, the odds of another economic downturn are high — and growing," Warren says.Politicsread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Trade tensions that could lead to layoffs and a pullback from consumers are at the center of the recession case.Economyread more
These are the stocks posting the largest moves midday.Market Insiderread more
Microsoft and OpenAI announced a new partnership to build artificial general intelligence to tackle more complex tasks than current AI.Technologyread more
There's a reason the film industry doesn't measure the success of modern movies against those of the past — movie ticket inflation isn't an exact science.Entertainmentread more
Swiss drugmaker Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI), a $2.4 billion transaction that values the U.S. genomic profiling group
at $5.3 billion, the partners said on Tuesday.
The deal, backed by the boards of both companies, is set to close in the second half of this year, they said in a statement.
The offer price represented a premium of 29 percent to FMI's closing price on Monday. FMI closed at $106.45, up 4.4 percent.
Based in Cambridge, Massachusetts, FMI is a molecular information company specialized in cancer care. It offers comprehensive genomic profiling (CGP) assays to identify molecular alterations in a patient's cancer and match them with targeted therapies, immunotherapies and clinical trials.
"This is important to our personalized healthcare strategy as we believe molecular insights and the broad availability of high quality comprehensive genomic profiling are key enablers for the development of, and access to, new cancer treatments," Roche pharmaceuticals head Daniel O'Day said.
"We will preserve FMI's autonomy while supporting them in accelerating their progress."
Citi is acting as financial advisers to Roche and Davis Polk & Wardwell LLP is legal counsel to Roche. Goldman Sachs & Co is financial adviser to the FMI Special Committee and Goodwin Procter LLP is legal counsel.